The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase 2 single-arm, open-label trial
Journal of Leukocyte Biology · 03.07.2026 · 118 (7)
DOI: 10.1093/jleuko/qiag083 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 18.06.2026. Verfasst von Carmela De Santo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Immunotherapy, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. Hauptthemen laut MEDLINE: Sialic Acid Binding Ig-like Lectin 3, Myeloid-Derived Suppressor Cells, Gemtuzumab, Neoplasms. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Little Princess Trust, Cancer Research UK.
Abstract (Originalsprache)
We previously demonstrated that the anti-CD33 antibody drug conjugate gemtuzumab ozogamicin (GO) binds CD33-expressing monocytic myeloid-derived suppressor cells (M-MDSCs), is internalized, and decreases those cells’ viability. Treatment of MDSCs with GO restores T-cell proliferation in co-culture, overcomes M-MDSC suppression of CAR-T cell proliferation, and enhances target-cell killing. Gemtuzumab Ozogamicin Therapy in Hemophagocytic Lymphohistiocytosis or Macrophage Activation Syndrome (GOTHAM) is a phase 2 single-arm clinical trial for which patients were eligible if they had a diagnosis of solid cancer with radiological or clinical evidence of disease progression, or primary or secondary hemophagocytic lymphohistiocytosis, or macrophage activation syndrome disease relapsing or refractory to treatment at enrollment. An initial regimen of 3 mg/m2 GO on days 1, 8, and 15 was tested, adjusted to 21-d intervals: days 1, 22, and 43. The primary outcome was the impact of GO therapy on peripheral CD33+ myeloid cells. Using 2 schedules of GO, we could not convincingly demonstrate safe feasibility in patients with solid cancer, because of neutropenia. However, GO reproducibly and significantly reduced circulating MDSCs. Importantly, there is consistent preliminary evidence that, upon rebound, the monocyte population of CD33+ cells is replaced with nonsuppressive monocytes. These data support the phase 1b dose-escalation testing of GO up to 2 mg/m2 in combination with immune checkpoint blockade and other immunotherapies in patients with solid cancer to find a dose that depletes and repolarizes MDSCs without causing undue neutropenia, paving the way to use GO as an immune potentiator in this patient population. Trial registration: ISRCTN 89158144
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Immunotherapy, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.
- Paediatric Oncology, Birmingham Children's Hospital, Birmingham, B4 6NH, United Kingdom.
- Clinical Immunology Service, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.
- Faculty of Health and Life Sciences, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool L69 7ZX, United Kingdom.
- Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.
ORCID-Profile: Lucinda Billingham, Su Lee, Gary Middleton
Förderung
- the Little Princess Trust
- Cancer Research UK
Zitieren
APA
De Santo, C., Jackson, A., Mussai, F., Al-Taei, S., Lal, N., Starkey, T., Fultang, L., McJannett, N., Kunene, V., Billingham, L., Lawson, A., Lee, S., Rogers, J., & Middleton, G. (2026). The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase 2 single-arm, open-label trial. Journal of Leukocyte Biology, 118(7). https://doi.org/10.1093/jleuko/qiag083
Vancouver
De Santo C, Jackson A, Mussai F, Al-Taei S, Lal N, Starkey T, et al. The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase 2 single-arm, open-label trial. Journal of Leukocyte Biology. 2026;118(7). doi:10.1093/jleuko/qiag083
BibTeX
@article{DeSanto2026,
author = {De Santo, Carmela and Jackson, Aimee and Mussai, Francis and Al-Taei, Saly and Lal, Neeraj and Starkey, Thomas and Fultang, Livingstone and McJannett, Nicola and Kunene, Victoria and Billingham, Lucinda and Lawson, Anna and Lee, Su and Rogers, Joseph and Middleton, Gary},
title = {The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase 2 single-arm, open-label trial},
journal = {Journal of Leukocyte Biology},
year = {2026},
volume = {118},
number = {7},
doi = {10.1093/jleuko/qiag083}
}
EUVIMED